Physician profile
Misty Corbin
NPI 1932647815
$823.33
in general payments reported to CMS, 2019-2025
13 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $134 · 2023: $257 · 2024: $143 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $207.94 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $121.90 | 2022-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $119.44 | 2022-2024 | Rybelsus, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.42 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $80.30 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $60.92 | 2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $31.90 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $31.35 | 2022-2023 | Bexsero, Shingrix |
| Corcept Therapeutics | $19.01 | 2024 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $15.53 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $14.78 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.73 | 2023 | Xifaxan |
| Abbvie INC. | $13.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misty Corbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.